This study is being conducted to further evaluate the safety and clinical outcomes of Coartem® Baby (artemether/lumefantrine 5 mg/60 mg) in neonates and infants weighing ≥2 kg to \<5 kg with uncomplicated malaria due to Plasmodium falciparum or mixed infections under real-world conditions.
Male or female neonates/infants
Body weight ≥ 2 kg to < 5kg
Confirmed diagnosis of uncomplicated infections due to Plasmodium falciparum or mixed infections including P. falciparum malaria by RDT or microscopy.
Eligible to receive Coartem® Baby dispersible tablets as per approved label
Known hypersensitivity to artemether, lumefantrine or to any of the excipients of Coartem® Baby.
Patients with severe malaria according to WHO definition (See Appendix 3).
Patients with a family history of congenital prolongation of the QTc interval or sudden death or with any other clinical condition known to prolong the QTc interval such as patients with a history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease.
Patients taking drugs that are known to prolong the QTc interval